• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

胸廓内动脉移植术生存获益的程度：绝对风险降低。

The magnitude of the survival benefit of internal thoracic artery grafting: Absolute risk reduction.

作者信息

Ohno Takayuki

机构信息

Cardiovascular Surgery and Intensive Care Unit, Mitsui Memorial Hospital, Tokyo, Japan.

出版信息

JTCVS Open. 2021 Nov 20;9:106-111. doi: 10.1016/j.xjon.2021.11.008. eCollection 2022 Mar.

DOI:10.1016/j.xjon.2021.11.008
PMID:36003479
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9390134/
Abstract

The magnitude of the survival benefit of CABG with internal thoracic artery graft increases with time over decades.

摘要

采用胸廓内动脉移植的冠状动脉旁路移植术（CABG）的生存获益程度在数十年间会随时间增加。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be44/9390134/1e6f5732f027/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be44/9390134/9fc4cfca1973/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be44/9390134/a5d29a75deef/fx2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be44/9390134/8b59334699f0/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be44/9390134/56f5fff71ff2/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be44/9390134/1e6f5732f027/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be44/9390134/9fc4cfca1973/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be44/9390134/a5d29a75deef/fx2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be44/9390134/8b59334699f0/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be44/9390134/56f5fff71ff2/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be44/9390134/1e6f5732f027/gr3.jpg

相似文献

1
The magnitude of the survival benefit of internal thoracic artery grafting: Absolute risk reduction.胸廓内动脉移植术生存获益的程度：绝对风险降低。
JTCVS Open. 2021 Nov 20;9:106-111. doi: 10.1016/j.xjon.2021.11.008. eCollection 2022 Mar.
2
Long-term survival benefit of internal thoracic artery grafting is negligible in a patient with bad ventricle.对于心室功能差的患者，胸廓内动脉移植的长期生存获益可忽略不计。
J Cardiovasc Surg (Torino). 1998 Feb;39(1):57-63.
3
Reusing the patent internal mammary artery as a conduit in redo coronary artery bypass surgery.在再次冠状动脉搭桥手术中复用胸廓内动脉作为血管桥。
Interact Cardiovasc Thorac Surg. 2016 Mar;22(3):346-50. doi: 10.1093/icvts/ivv338. Epub 2015 Dec 15.
4
Long-Term Outcomes in Coronary Artery Bypass Graft Patients Using Internal Thoracic Artery with Ipsilateral Arteriovenous Shunt for Hemodialysis.使用胸廓内动脉联合同侧动静脉分流进行血液透析的冠状动脉旁路移植患者的长期预后
Acta Cardiol Sin. 2019 Jul;35(4):387-393. doi: 10.6515/ACS.201907_35(4).20181208A.
5
Statin treatment equalizes long-term survival between patients with single and bilateral internal thoracic artery grafts.他汀类药物治疗可使接受单侧和双侧胸廓内动脉移植的患者长期生存率相等。
Ann Thorac Surg. 2009 Sep;88(3):789-95; discussion 795. doi: 10.1016/j.athoracsur.2009.04.097.
6
[Ten-year survival and cardiac event-free rates in Japanese patients with the left anterior descending artery revascularized with internal thoracic artery or saphenous vein graft: a comparative study].[日本患者左前降支动脉采用胸廓内动脉或大隐静脉移植进行血运重建后的十年生存率及无心脏事件发生率：一项比较研究]
Nihon Geka Gakkai Zasshi. 1996 Mar;97(3):202-9.
7
Sequential internal thoracic artery bypass is safe but does not improve survival.序贯内乳动脉旁路术是安全的，但不能提高生存率。
Ann Thorac Surg. 2014 Jul;98(1):23-9. doi: 10.1016/j.athoracsur.2014.03.036. Epub 2014 May 13.
8
[Redo coronary artery bypass grafting using the patent left internal thoracic artery graft as an in flow with composite internal thoracic artery Y grafting; report of a case].[采用通畅的左胸廓内动脉移植物作为流入道行复合胸廓内动脉Y形移植物再次冠状动脉旁路移植术；1例报告]
Kyobu Geka. 2002 Sep;55(10):891-4.
9
Off-pump bilateral internal thoracic artery grafting in right internal thoracic artery to right coronary system.非体外循环下双侧内乳动脉桥移植于右内乳动脉至右冠状动脉系统。
Ann Thorac Surg. 2012 Sep;94(3):717-24. doi: 10.1016/j.athoracsur.2012.04.066. Epub 2012 Jul 15.
10
Saphenous vein as a composite graft from the internal thoracic artery.大隐静脉作为胸廓内动脉的复合移植物。
Ann Cardiothorac Surg. 2018 Sep;7(5):686-689. doi: 10.21037/acs.2018.06.08.

引用本文的文献

1
Commentary: Long-term outcomes after internal thoracic artery grafting: Where does the time go?评论：胸廓内动脉移植后的长期结局：时间都去哪儿了？
JTCVS Open. 2022 Jan 20;9:114-115. doi: 10.1016/j.xjon.2022.01.011. eCollection 2022 Mar.
2
Commentary: Coronary revascularization therapies and number needed to treat.评论：冠状动脉血运重建治疗与需治疗人数
JTCVS Open. 2022 Jan 20;9:112-113. doi: 10.1016/j.xjon.2022.01.012. eCollection 2022 Mar.

本文引用的文献

1
Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial.经皮冠状动脉介入治疗与冠状动脉旁路移植术治疗无保护左主干狭窄：NOBLE 随机非劣效性试验的 5 年更新结果。
Lancet. 2020 Jan 18;395(10219):191-199. doi: 10.1016/S0140-6736(19)32972-1. Epub 2019 Dec 23.
2
Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease.左主干冠状动脉疾病经皮冠状动脉介入治疗或冠状动脉旁路移植术后 5 年的结果。
N Engl J Med. 2019 Nov 7;381(19):1820-1830. doi: 10.1056/NEJMoa1909406. Epub 2019 Sep 28.
3
Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial.
经皮冠状动脉介入治疗与冠状动脉旁路移植术治疗三血管病变或左主干病变患者：多中心随机对照 SYNTAX 试验 10 年随访结果。
Lancet. 2019 Oct 12;394(10206):1325-1334. doi: 10.1016/S0140-6736(19)31997-X. Epub 2019 Sep 2.
4
Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data.冠状动脉旁路移植术与经皮冠状动脉介入治疗支架置入治疗冠状动脉疾病的死亡率：一项个体患者数据的合并分析。
Lancet. 2018 Mar 10;391(10124):939-948. doi: 10.1016/S0140-6736(18)30423-9. Epub 2018 Feb 23.
5
Influence of Diabetes on Long-Term Coronary Artery Bypass Graft Patency.糖尿病对冠状动脉旁路移植术通畅率的影响。
J Am Coll Cardiol. 2017 Aug 1;70(5):515-524. doi: 10.1016/j.jacc.2017.05.061.
6
Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease.依维莫司洗脱支架或旁路移植术治疗左主干冠状动脉疾病。
N Engl J Med. 2016 Dec 8;375(23):2223-2235. doi: 10.1056/NEJMoa1610227. Epub 2016 Oct 31.
7
Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy.缺血性心肌病患者的冠状动脉搭桥手术
N Engl J Med. 2016 Apr 21;374(16):1511-20. doi: 10.1056/NEJMoa1602001. Epub 2016 Apr 3.
8
Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease.经皮冠状动脉介入治疗对稳定型缺血性心脏病患者长期生存的影响。
N Engl J Med. 2015 Nov 12;373(20):1937-46. doi: 10.1056/NEJMoa1505532.
9
Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial.冠状动脉旁路移植术与经皮冠状动脉介入治疗对三血管病变患者的比较：SYNTAX 试验的最终五年随访结果。
Eur Heart J. 2014 Oct 21;35(40):2821-30. doi: 10.1093/eurheartj/ehu213. Epub 2014 May 21.
10
Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial.冠状动脉旁路移植术与经皮冠状动脉介入治疗在三支病变合并左主干病变患者中的比较：随机、临床 SYNTAX 试验的 5 年随访结果。
Lancet. 2013 Feb 23;381(9867):629-38. doi: 10.1016/S0140-6736(13)60141-5.